Antiosteoporotic medications initiated immediately after fracture do not impair healing despite clinical concerns, and their early use reduces refracture risk in older adults. This addresses a persistent treatment hesitation that may delay protection against secondary fractures in a vulnerable population.
Key Points
- Early antiosteoporotic treatment does not delay fracture healing
- Antiresorptive agents safely reduce subsequent fracture risk post-injury
- Clinical hesitation to treat immediately leaves patients exposed to refracture
Longevity Analysis
Fragility fractures function as a critical inflection point in aging — they signal both compromised structural integrity and accelerated functional decline. The evidence that antiosteoporotic medications can be initiated without healing complications removes a significant barrier to intervention. For practitioners managing older adults, this clarifies the decision framework: the risk of inaction (allowing progressive bone loss and refracture vulnerability) substantially outweighs the theoretical risk of treatment interference. Early intervention preserves both skeletal resilience and functional independence during a window when these remain recoverable.
Original published by The Lancet Healthy Longevity, by Julien Paccou.